2012
IL-21 Receptor Is Required for the Systemic Accumulation of Activated B and T Lymphocytes in MRL/MpJ-Faslpr/lpr/J Mice
Rankin AL, Guay H, Herber D, Bertino SA, Duzanski TA, Carrier Y, Keegan S, Senices M, Stedman N, Ryan M, Bloom L, Medley Q, Collins M, Nickerson-Nutter C, Craft J, Young D, Dunussi-Joannopoulos K. IL-21 Receptor Is Required for the Systemic Accumulation of Activated B and T Lymphocytes in MRL/MpJ-Faslpr/lpr/J Mice. The Journal Of Immunology 2012, 188: 1656-1667. PMID: 22231702, PMCID: PMC3618484, DOI: 10.4049/jimmunol.1003871.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAutoantibodiesAutoimmunityB-LymphocytesCD4-Positive T-LymphocytesCell DifferentiationInterferon-gammaInterleukinsLupus Erythematosus, SystemicLymphatic DiseasesLymphocyte ActivationMiceMice, Inbred MRL lprMice, KnockoutReceptors, Interleukin-21SkinSplenomegalyT-Lymphocyte SubsetsT-Lymphocytes, Helper-InducerConceptsT cell effector subsetsIL-21Effector subsetsIL-21RT cellsHelper cellsSpontaneous germinal center formationIL-21-dependent mannerIL-21 receptorMRL/MpJPlasma cell accumulationGerminal center formationTh cell differentiationSignificant reductionAutoantibody titersAutoantibody productionCytokines IFNImmune activationSystemic autoimmunityJ miceDisease manifestationsT lymphocytesPleiotropic cytokineB cellsDisease pathogenesis
2011
Systemic Autoimmunity and Lymphoproliferation Are Associated with Excess IL-7 and Inhibited by IL-7Rα Blockade
Gonzalez-Quintial R, Lawson BR, Scatizzi JC, Craft J, Kono DH, Baccala R, Theofilopoulos AN. Systemic Autoimmunity and Lymphoproliferation Are Associated with Excess IL-7 and Inhibited by IL-7Rα Blockade. PLOS ONE 2011, 6: e27528. PMID: 22102903, PMCID: PMC3213145, DOI: 10.1371/journal.pone.0027528.Peer-Reviewed Original ResearchConceptsT cellsIL-7Systemic autoimmunityIL-7R blockadeIL-7Rα blockadeAutoreactive T cellsMemory T cellsAdvanced disease stageProgression of autoimmunityFibroblastic reticular cellsNovel therapeutic approachesT cell activationAutoimmune manifestationsAutoimmune syndromeCommensal antigensDisease stageIL-7RαTherapeutic approachesLymphocyte homeostasisCell activationReticular cellsAutoimmunityMarked accumulationLupusBlockade
2006
Abrogation of skin disease in LUPUS‐prone MRL/FASlpr mice by means of a novel tylophorine analog
Choi J, Gao W, Odegard J, Shiah H, Kashgarian M, McNiff JM, Baker DC, Cheng Y, Craft J. Abrogation of skin disease in LUPUS‐prone MRL/FASlpr mice by means of a novel tylophorine analog. Arthritis & Rheumatism 2006, 54: 3277-3283. PMID: 17009262, DOI: 10.1002/art.22119.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusEnd-organ diseaseInflammatory skin diseaseMRL/Skin diseasesMRL/Faslpr miceFemale MRL/NF-kappaB inhibitorFlow cytometric analysisFaslpr miceAutoantibody titersIgG levelsLupus erythematosusLymph nodesRenal diseaseVehicle treatmentKidney diseaseHepatic toxicityTotal IgMTylophorine analogsAntichromatin autoantibodiesTherapeutic effectHistopathologic analysisMurine modelSignificant abrogation